ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

• Status: Unknown status
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to use an approved drug(Visudyne) for neovascular age-related macular degeneration, which is essentially choroidal neovascularization for permeability and vascular proliferation for the retinal circulation, to treat another permeable abnormality - retinal capillary abnormalities - located eccentric to the central portion of the macula or in the foveal region.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Manhattan Eye, Ear & Throat Hospital
• Treatments: Verteporfin

Criteria

Inclusion Criteria:• Individuals that are 50 years of age and older.

• Patients with retinal capilary abnormalities/vascular diseases such as macular telangiectasia type I and type II, retinal arteriolar macroanurysms, and retinal angiomous proliferation (RAP).

• Patients with diabetic retinopathy and branch retinal vein occlusions

• Other patients who are non-responders to approved treatment methods

Exclusion Criteria:

• Patients whose diseases have approved methods of treatment.

• Pregnant women or women of normal child bearing age.